Preface |
|
ix | |
Acknowledgments |
|
x | |
About the Executive Editors |
|
x | |
Introduction to Ophthalmology |
|
1 | (1) |
Resources from the American Academy of Ophthalmology |
|
1 | (1) |
Meet the Eye Care Team |
|
1 | (2) |
Eye Myths |
|
3 | (4) |
|
|
7 | (34) |
|
|
7 | (1) |
|
|
7 | (1) |
|
|
8 | (8) |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
9 | (5) |
|
|
14 | (2) |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
17 | (17) |
|
|
17 | (1) |
|
Distance Visual Acuity Testing |
|
|
17 | (3) |
|
Near Visual Acuity Testing |
|
|
20 | (2) |
|
Visual Acuity Estimation in an Uncooperative Patient |
|
|
22 | (1) |
|
Confrontation Visual Field Testing |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
23 | (1) |
|
|
23 | (1) |
|
|
24 | (1) |
|
Pupillary Reaction Testing |
|
|
25 | (1) |
|
Anterior Chamber Depth Assessment |
|
|
25 | (1) |
|
Intraocular Pressure Measurement |
|
|
26 | (2) |
|
|
28 | (1) |
|
Fluorescein Staining of Cornea |
|
|
28 | (2) |
|
|
30 | (4) |
|
Summary of Steps in the Eye Examination |
|
|
34 | (1) |
|
|
34 | (2) |
|
|
35 | (1) |
|
Abnormal Fundus Appearance |
|
|
35 | (1) |
|
Shallow Anterior Chamber Depth/Elevated Intraocular Pressure |
|
|
36 | (1) |
|
|
36 | (1) |
|
|
36 | (2) |
|
|
38 | (3) |
|
|
41 | (18) |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
42 | (1) |
|
Narrowing the Diagnosis From the History |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
Confrontation Visual Field Testing |
|
|
43 | (1) |
|
|
43 | (1) |
|
Red Reflex Evaluation and Ophthalmoscopy |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
44 | (1) |
|
How to Interpret the Findings |
|
|
44 | (11) |
|
Acute Vision Loss Associated With Pain |
|
|
44 | (1) |
|
Acute Vision Loss Without Pain |
|
|
45 | (1) |
|
Painless, Acute Vision Loss Without Clear Media |
|
|
45 | (2) |
|
Painless, Acute Vision Loss With Clear Media |
|
|
47 | (8) |
|
|
55 | (1) |
|
|
55 | (1) |
|
|
56 | (1) |
|
|
57 | (2) |
|
|
59 | (28) |
|
|
59 | (1) |
|
|
59 | (1) |
|
|
60 | (1) |
|
|
60 | (9) |
|
|
63 | (3) |
|
|
66 | (1) |
|
|
66 | (1) |
|
How to Interpret the Findings |
|
|
67 | (2) |
|
|
69 | (1) |
|
|
69 | (5) |
|
|
70 | (2) |
|
|
72 | (1) |
|
|
73 | (1) |
|
How to Interpret the Findings |
|
|
73 | (1) |
|
|
74 | (1) |
|
|
74 | (7) |
|
|
74 | (3) |
|
|
77 | (1) |
|
|
78 | (1) |
|
How to Interpret the Findings |
|
|
79 | (1) |
|
|
79 | (1) |
|
The Visually Impaired Patient |
|
|
80 | (1) |
|
|
81 | (1) |
|
|
81 | (2) |
|
|
83 | (4) |
|
|
87 | (26) |
|
|
87 | (1) |
|
|
87 | (1) |
|
|
88 | (3) |
|
|
88 | (1) |
|
|
88 | (3) |
|
Disorders Associated With a Red Eye |
|
|
91 | (6) |
|
The Acute, Painful Red Eye |
|
|
91 | (2) |
|
Acute, Nonpainful Red Eye |
|
|
93 | (2) |
|
Chronic, Irritated Red Eye |
|
|
95 | (1) |
|
Chronic Red Eye Without Irritation |
|
|
96 | (1) |
|
|
96 | (1) |
|
Further Interpretation of the Findings |
|
|
97 | (5) |
|
|
97 | (2) |
|
|
99 | (2) |
|
Associated Systemic Problems |
|
|
101 | (1) |
|
|
102 | (1) |
|
|
102 | (5) |
|
|
103 | (2) |
|
|
105 | (1) |
|
Subconjunctival Hemorrhage |
|
|
106 | (1) |
|
|
106 | (1) |
|
|
107 | (1) |
|
|
107 | (1) |
|
|
108 | (4) |
|
|
112 | (1) |
|
5 Ocular and Orbital Injuries |
|
|
113 | (24) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
114 | (3) |
|
|
114 | (3) |
|
|
117 | (1) |
|
|
117 | (4) |
|
|
118 | (1) |
|
|
118 | (1) |
|
|
119 | (1) |
|
|
120 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (1) |
|
|
121 | (4) |
|
|
122 | (1) |
|
|
122 | (3) |
|
|
125 | (4) |
|
|
126 | (1) |
|
|
126 | (1) |
|
Prescribing Eye Medication |
|
|
126 | (2) |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
130 | (4) |
|
|
134 | (3) |
|
6 Amblyopia and Strabismus |
|
|
137 | (20) |
|
|
137 | (1) |
|
|
137 | (1) |
|
|
138 | (4) |
|
|
138 | (2) |
|
|
140 | (2) |
|
How to Examine and Interpret the Findings |
|
|
142 | (8) |
|
|
143 | (2) |
|
|
145 | (4) |
|
|
149 | (1) |
|
|
150 | (2) |
|
|
150 | (1) |
|
|
151 | (1) |
|
Serious Intraocular Lesions |
|
|
152 | (1) |
|
|
152 | (1) |
|
|
153 | (2) |
|
|
155 | (2) |
|
|
157 | (32) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
158 | (5) |
|
|
158 | (1) |
|
|
158 | (1) |
|
Color Perception and Saturation |
|
|
159 | (1) |
|
|
159 | (3) |
|
|
162 | (1) |
|
|
163 | (1) |
|
How to Interpret the Findings |
|
|
163 | (20) |
|
|
163 | (4) |
|
|
167 | (5) |
|
|
172 | (1) |
|
|
173 | (7) |
|
|
180 | (2) |
|
|
182 | (1) |
|
Cognitive Vision Loss: The Visual Variant of Alzheimer's Disease |
|
|
182 | (1) |
|
|
183 | (1) |
|
|
183 | (4) |
|
|
187 | (2) |
|
8 Eyelid, Lacrimal, and Orbital Disease |
|
|
189 | (22) |
|
|
189 | (1) |
|
|
189 | (1) |
|
|
190 | (8) |
|
|
190 | (1) |
|
|
191 | (6) |
|
|
197 | (1) |
|
|
198 | (2) |
|
|
200 | (5) |
|
|
200 | (1) |
|
|
201 | (2) |
|
Inflammatory Processes of the Orbit |
|
|
203 | (1) |
|
|
204 | (1) |
|
|
205 | (1) |
|
|
206 | (3) |
|
|
209 | (2) |
|
9 Ocular Manifestations of Systemic Disease |
|
|
211 | (20) |
|
|
211 | (1) |
|
|
211 | (1) |
|
|
212 | (4) |
|
|
216 | (3) |
|
|
216 | (1) |
|
|
217 | (1) |
|
|
218 | (1) |
|
|
218 | (1) |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
220 | (1) |
|
Sarcoidosis and Other Inflammatory and Autoimmune Conditions |
|
|
221 | (2) |
|
|
222 | (1) |
|
|
223 | (1) |
|
Acquired Immunodeficiency Syndrome |
|
|
223 | (2) |
|
|
225 | (1) |
|
Other Systemic Infections |
|
|
226 | (1) |
|
|
227 | (1) |
|
|
227 | (2) |
|
|
229 | (2) |
|
|
231 | (22) |
|
|
231 | (1) |
|
|
231 | (2) |
|
|
233 | (1) |
|
Topical Ocular Diagnostic Drugs |
|
|
234 | (2) |
|
|
234 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
Topical Ocular Therapeutic Drugs |
|
|
236 | (2) |
|
|
236 | (1) |
|
Agents for Relief of Allergic Conjunctivitis |
|
|
237 | (1) |
|
|
237 | (1) |
|
Agents for the Relief of Dry Eye Symptoms |
|
|
237 | (1) |
|
|
238 | (1) |
|
|
238 | (1) |
|
Systemic Side Effects of Glaucoma Medications |
|
|
238 | (4) |
|
|
239 | (1) |
|
Cholinergic-Stimulating Drugs |
|
|
240 | (1) |
|
α2.-Adrenoceptor Agonists |
|
|
240 | (1) |
|
Adrenergic-Stimulating Drugs |
|
|
241 | (1) |
|
|
241 | (1) |
|
Carbonic Anhydrase Inhibitors |
|
|
241 | (1) |
|
Ocular Side Effects of Systemic Drugs |
|
|
242 | (6) |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
243 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
HMG-COA Reductase Inhibitors (Statins) |
|
|
245 | (1) |
|
|
246 | (1) |
|
Sildenafil, Tadalafil, Vardenafil, and Avanafil |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (3) |
|
|
251 | (2) |
Index |
|
253 | |